TABLE 1.
Antimicrobial agent | MIC (μg/ml) in: |
|||
---|---|---|---|---|
Patient B for: |
Patient H for: |
|||
K. pneumoniae 01140-2 (KPC-31, ST258) | E. hormaechei 04408-5 (KPC-40, ST407) | K. pneumoniae 04409-2 (KPC-31, ST258) | E. hormaechei 04409-1 (KPC-40, ST407) | |
Ceftazidime-avibactama | 64 | 16 | 4 | 8 |
Ertapenem | >4 | 4 | >4 | 2 |
Imipenem | >8 | ≤1 | >8 | ≤1 |
Meropenem | >8 | ≤1 | >8 | ≤1 |
Cefotaxime | >32 | >32 | >32 | >32 |
Ceftazidime | >16 | >16 | >16 | >16 |
Cefepime | >16 | 8 | >16 | 8 |
Aztreonam | >16 | >16 | >16 | >16 |
Piperacillin-tazobactam | >64/4 | >64/4 | >64/4 | >64/4 |
Ciprofloxacin | >2 | ≤0.25 | >2 | ≤0.25 |
Levofloxacin | >8 | ≤1 | >8 | ≤1 |
Gentamicin | ≤1 | ≤1 | ≤1 | ≤1 |
Amikacin | 16 | ≤4 | 16 | ≤4 |
Tobramycin | >8 | ≤1 | >8 | ≤1 |
Doxycycline | >16 | 16 | >16 | 16 |
Tigecycline | 1 | 2 | 1 | 2 |
Colistin | ≤0.25 | ≤0.25 | ≤0.25 | ≤0.25 |
The breakpoint for ceftazidime-avibactam approved by the Clinical and Laboratory Standards Institute is ≤8/4 μg/ml for susceptible and ≥16/4 μg/ml for resistance.